Directional atherectomy in peripheral and coronary interventions — the catheter-based plaque excision technique using a rotating blade cutting in a specific direction with collection of removed material in a chamber for retrieval — represents the fastest-growing plaque modification technology in the global atherectomy system market, with the Atherectomy System Market reflecting directional atherectomy advancement as the premium growth commercial driver.

The peripheral artery disease epidemic — the CDC reporting approximately 6.5 million people aged 40 and older in the U.S. living with PAD, with heart disease remaining the leading cause of death accounting for more than 700,000 deaths annually, creating the massive procedural demand for plaque modification. The atherectomy devices market valued at USD 1.1 billion in 2025 and projected to reach USD 2.5 billion by 2035 at an 8.5% CAGR, with directional atherectomy devices anticipated to capture 38.8% market share by 2035. The lower extremity PAD segment retaining a leading position fueled by high prevalence and the accelerating transition toward endovascular-first treatment approaches.

Imaging-guided and combined-modality innovation — the advancement of various atherectomy technologies including directional, rotational, orbital, and laser systems coupled with a rising preference for minimally invasive peripheral interventions and vessel-preserving strategies. The Royal Philips enrollment in November 2024 of the first patient in the U.S. THOR IDE clinical trial for an innovative combined laser atherectomy and intravascular lithotripsy catheter integrating two critical PAD treatments into a single device. The Johnson & Johnson launch in May 2026 of the Shockwave C2 Aero Coronary IVL Catheter designed for enhanced lesion crossing and improved deliverability for calcified coronary artery disease.

Orbital and rotational calcified lesion management — the orbital atherectomy using a diamond-coated crown orbiting around the artery to sand down plaque particularly useful for heavily calcified lesions, and rotational atherectomy employing a high-speed rotating burr to grind away calcified plaque effective for ostial and heavily calcified lesions that cannot be dilated with balloon angioplasty. The Abbott acquisition of Cardiovascular Systems Inc. (CSI) in April 2023 bringing the Diamondback 360 orbital atherectomy system into its portfolio for peripheral and coronary calcified lesion treatment.

Do you think combined-modality devices integrating atherectomy with intravascular lithotripsy or drug-coated balloons will eventually replace standalone atherectomy systems, or will the need for procedure flexibility and cost-effectiveness maintain separate device utilization?

What are the leading atherectomy system products and their clinical applications? Leading atherectomy system products: Boston Scientific SilverHawk/TurboHawk (directional atherectomy, peripheral plaque excision, collection chamber, TURBO-Power); Medtronic HawkOne (directional, peripheral, integrated, user-friendly); Cardiovascular Systems Inc./Abbott Diamondback 360 (orbital atherectomy, diamond-coated crown, calcified lesions, coronary and peripheral); Boston Scientific Rotablator (rotational atherectomy, high-speed burr, calcified coronary lesions); Philips Auryon (laser atherectomy, photoablation, chronic total occlusions, peripheral); AngioDynamics Auryon XL (laser, 225-cm radial access, FDA cleared January 2024); Ra Medical Systems (excimer laser, peripheral, thrombus-containing lesions); Straub Medical Rotarex (rotational, thrombus and plaque, peripheral); Rex Medical Fetch (directional, single-use, cost-effective); Key technologies: Directional atherectomy (38.8% projected share, 2035 — plaque excision, collection, anatomically challenging vessels); Rotational atherectomy (<5% of PCI, calcified, inelastic lesions, burr entrapment risk); Orbital atherectomy (heavily calcified, sanding action, lower embolization); Laser atherectomy (soft/fibrous plaques, chronic total occlusions, photoablation); Applications: Peripheral vascular (femoropopliteal, below-the-knee, iliac); Coronary artery (calcified lesions, in-stent restenosis); Chronic total occlusions; Calcified lesions (primary indication for orbital/rotational); Thrombus-containing lesions (laser, rotational).

What is the market size and competitive landscape for atherectomy systems? Atherectomy system market economics: Market size 2025: USD 1.1 billion; 2026: USD 1.2 billion; 2035: USD 2.5 billion; CAGR: 8.5% (Research Nester); Alternative estimates: USD 866.4 million (2025) to USD 1.6 billion (2033) at 6.2% CAGR (GMI); USD 1.05 billion (2025) to USD 1.58 billion (2034) at 4.62% CAGR (Renub); USD 1.11 billion (2026) to USD 1.54 billion (2030) at 8.6% CAGR (Research and Markets); Segments: Directional (38.8% projected share, 2035); Orbital (calcified lesions); Rotational (coronary, <5% of PCI); Laser (chronic total occlusions, soft plaque); Applications: Lower extremity PAD (leading); Coronary (growing); End users: Hospitals (49.1% share); ASCs (fastest-growing); Specialty clinics; Regional: North America (43.4% share by 2035, largest); Asia-Pacific (fastest-growing); Europe (30% share); Key players: Boston Scientific (SilverHawk, Rotablator, market leader); Medtronic (HawkOne, directional); Abbott (Diamondback 360, CSI acquisition); Philips (Auryon laser, THOR trial); Cardiovascular Systems Inc. (now Abbott, orbital); AngioDynamics (Auryon XL laser); Ra Medical Systems (excimer laser); Straub Medical (Rotarex); Rex Medical (Fetch); Shockwave Medical (IVL, calcified lesion); Pricing: Directional catheter: $1,500-3,000; Orbital system: $2,000-4,000; Rotational burr: $1,000-2,500; Laser catheter: $2,500-5,000; Procedure cost: $5,000-15,000; Growth drivers: PAD prevalence, diabetes (589M adults worldwide), aging population, endovascular-first approach, minimally invasive preference, imaging integration, calcified lesion complexity, ASC expansion.

#AtherectomySystem #DirectionalAtherectomy #PeripheralArteryDisease #PlaqueModification #CalcifiedLesions #Endovascular #Cardiovascular